MedTrust Online is for oncology healthcare professionals only.
|
||
Welcome
MedTrust Online connects oncologists with the latest clinical discoveries to improve patient care.
Exiqon Diagnostics Launches the First Molecular Diagnostics Industry Content Portal on MedTrust Online
Exiqon Diagnostics, a wholly owned subsidiary of Exiqon A/S, is a leader in personalizing medicine for cancer patients. As a CLIA and CAP-certified laboratory, Exiqon Diagnostics develops and performs novel molecular and cell-based oncology assays to help physicians individualize and optimize treatment selection for their patients. In addition to the Extreme Drug Resistance (EDR®) Assay, Exiqon Diagnostics offers an extensive test menu of prognostic and predictive molecular oncology biomarkers such as KRAS and BRAF mutation analyses for a more comprehensive evaluation of treatment options
KRAS and BRAF Symposium Hosted by Dr. Alex Adjei Now Live!
Click here to participate in the discussion
OncoAssist Advisory Board
MedTrust Online has recruited a board of advisors of international stature. Each member is recognized as the leading expert in their respective field. As a member, you get unprecedented access to their expertise, knowledge and experience. Learn more about our Advisory Board here.
MTOL in the News
- MedTrust Online Surpasses 5,000 Users and Adds Dr. Henry Friedman To Oncology Advisory Board,
Scottsdale, AZ- September 17, 2009- MedTrust Online, a world-leading provider of clinically-useful knowledge for oncologists seeking therapy options for challenging patient cancer cases, has surpassed 5,000 registered users on its free portal, Oncocentric.com. MedTrust Online also announced today that world-renowned oncologist Dr. Henry Friedman has joined MedTrust Online’s growing board of oncology advisors.